Royalty Pharma (RPRX) CFO-linked entities execute planned share sales

Rhea-AI Filing Summary

Royalty Pharma plc EVP & CFO Terrance P. Coyne, through affiliated entities, reported planned open-market sales of Class A Ordinary Shares. On April 1, 2026, TPC RP EPA1 LLC sold 1,875 shares and TPC RP 2021, LLC sold 32,916 shares at a weighted average price of $48.3318 per share, all under a Rule 10b5-1 trading plan adopted on August 8, 2025. After these sales, TPC RP EPA1 LLC held 42,011 shares and TPC RP 2021, LLC held 32,916 shares. Additional holdings reported include 24,170 shares in a spouse’s IRA, 23,270 shares in an IRA, 1,500 shares held directly, and 1,450 shares held by a spouse, indicating that the transactions represent a partial reduction of a larger overall position.

Insights

Equity compensation and insider-trading specialist

Pre-planned insider share sales under a 10b5-1 plan look routine and not thesis-changing.

The EVP & CFO is linked to two entities that sold a combined 34,791 Class A Ordinary Shares of Royalty Pharma plc on April 1, 2026. Both transactions were coded as open-market sales at a weighted average price of $48.3318 per share.

A footnote states the sales were executed under a Rule 10b5-1 trading plan adopted on August 8, 2025, suggesting they were pre-scheduled rather than opportunistic. The filing also shows substantial remaining holdings across multiple indirect accounts and a direct position, so these sales reflect a partial portfolio adjustment rather than an exit.

Given the pre-planned nature and continuing sizable stake, this activity generally reads as routine liquidity management. Future company filings may provide additional context if the overall ownership position changes materially over time.

Insider Trade Summary 10b5-1

Net Seller: 34,791 shares ($1,681,512)

Net Sell 6 txns

Insider Coyne Terrance P.

Role EVP & CFO

Sold 34,791 shs ($1.68M)

Type	Security	Shares	Price	Value
Sale	Class A Ordinary Shares	1,875	$48.3318	$91K
Sale	Class A Ordinary Shares	32,916	$48.3318	$1.59M
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--

Holdings After Transaction: Class A Ordinary Shares — 42,011 shares (Indirect, TPC RP EPA1 LLC); Class A Ordinary Shares — 1,500 shares (Direct)

Footnotes (1)

1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.07 to $48.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold by TPC RP EPA1 LLC: 1,875 shares Shares sold by TPC RP 2021, LLC: 32,916 shares Total net shares sold: 34,791 shares +5 more

8 metrics

Shares sold by TPC RP EPA1 LLC 1,875 shares Open-market sale of Class A Ordinary Shares on April 1, 2026

Shares sold by TPC RP 2021, LLC 32,916 shares Open-market sale of Class A Ordinary Shares on April 1, 2026

Total net shares sold 34,791 shares Net-sell direction across reported transactions

Weighted average sale price $48.3318 per share Average price across multiple trades in the sale range

Shares held by TPC RP EPA1 LLC after sale 42,011 shares Indirect holdings following April 1, 2026 transactions

Shares held by TPC RP 2021, LLC after sale 32,916 shares Indirect holdings following April 1, 2026 transactions

Shares in spouse’s IRA 24,170 shares Indirect holdings reported as of April 1, 2026

Directly held shares 1,500 shares Direct ownership of Class A Ordinary Shares

Key Terms

Rule 10b5-1 plan, weighted average price, open-market sale, Class A Ordinary Shares, +1 more

5 terms

Rule 10b5-1 plan regulatory

"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average price financial

"The reported price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Class A Ordinary Shares financial

"security_title: Class A Ordinary Shares"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

indirect ownership financial

"ownership_type: indirect"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coyne Terrance P.

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 EAST 59TH STREET

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	04/01/2026		S(1)		1,875	D	$48.3318(2)	42,011	I	TPC RP EPA1 LLC
Class A Ordinary Shares	04/01/2026		S(1)		32,916	D	$48.3318(2)	32,916	I	By TPC RP 2021, LLC
Class A Ordinary Shares								24,170	I	By Spouse's IRA
Class A Ordinary Shares								23,270	I	By IRA
Class A Ordinary Shares								1,500	D
Class A Ordinary Shares								1,450	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.07 to $48.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 6,448,180 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,807,277 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.

	/s/ Sean Weisberg, as Attorney-in-Fact for Terrance P. Coyne	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Royalty Pharma (RPRX) report for Terrance P. Coyne?

Royalty Pharma reported that entities associated with EVP & CFO Terrance P. Coyne sold Class A Ordinary Shares in two open-market transactions. These involved thousands of shares and were executed under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025.

How many Royalty Pharma shares were sold in the latest Form 4 for RPRX?

The Form 4 shows two open-market sales totaling 34,791 Class A Ordinary Shares. One trade covered 1,875 shares by TPC RP EPA1 LLC and the other 32,916 shares by TPC RP 2021, LLC, both at a weighted average price of $48.3318.

At what price did the Royalty Pharma CFO-linked entities sell RPRX shares?

The reported weighted average sale price was $48.3318 per share. A footnote explains the shares were sold in multiple trades between $48.07 and $48.67 per share, with detailed trade breakdowns available on written request to the issuer or regulators.

Were the recent Royalty Pharma (RPRX) insider sales pre-planned under Rule 10b5-1?

Yes. A footnote states that all reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025. Such plans automate trades over time, reducing the significance of day-to-day timing decisions.

How many Royalty Pharma shares does Terrance P. Coyne still hold after these sales?

After the sales, the filing shows 42,011 shares held by TPC RP EPA1 LLC and 32,916 shares by TPC RP 2021, LLC, plus additional indirect and direct holdings. These include stakes in IRAs, a spouse’s IRA, a spouse’s account, and 1,500 shares held directly.

What types of accounts hold Royalty Pharma (RPRX) shares for the CFO after the Form 4 trades?

Holdings are spread across several account types: two LLCs associated with the reporting person, a spouse’s IRA, the reporting person’s IRA, a spouse’s personal holdings, and a direct personal holding. This diversification reflects multiple indirect ownership structures in addition to direct ownership.